Abstract: Provided herein are in vitro methods for diagnosing an immediate hypersensitivity reaction (IHR) against a small compound or a drug in a subject, comprising the steps of (a) contacting mast cells with serum obtained from said subject; (b) contacting the mast cells obtained in step (a) with said small compound or said drug; (c) detecting mast cell activation and/or degranulation of the mast cells obtained in step (b); and (d) attributing the detection or no detection of mast cell activation and/or degranulation to a particular diagnosis of IHR.

Abstract: The present invention relates to compounds for use in the prevention and/or treatment of PAR-related diseases, such as for example: pain and ocular disorders. More in particular, the present invention provides bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of pancreatitis-related pain, IBS (irritable bowel syndrome), IBD (inflammatory bowel disease), dry eye disease and conjunctivitis sicca. These inhibitors were found to have a different inhibitory profile compared to diphenyl guanidinophenylethylphosphonates leading to a more pronounced effect on these conditions.

Abstract: The current invention relates to long ?-? di-functional linear molecules as building blocks closing the gap between small molecules and polymers, or in a polycondensated form, in the production of oligomers and/or polymers, surfactants, lubricants, coatings, colloidal stabilizing surface chains/molecules.

Abstract: The present invention relates to a method and system for obtaining an interaction property between a molecule or biomolecule or particle or bioparticle or nano- or microparticle on the one hand and a target particle on the other hand. The method comprises obtaining potentiometric titration results for a potentiometric measurement during titration of a solution with a titrant, said solution being a solution of one of a ligand of the target particle or said molecule or biomolecule or particle or bioparticle or nano- or microparticle. Said titrant comprises the other of said target particle ligand or said molecule or biomolecule or particle or bioparticle or nano- or microparticle. The method also comprises deriving based on said potentiometric titration results an interaction property between said molecule or biomolecule or particle or bioparticle or nano- or microparticle and said target particle.

Abstract: The invention concerns KDM5A inhibitors for use in prevention or treatment of idiopathic inflammatory myopathies such as polymyositis, dermatomyositis, necrotizing autoimmune myopathy, and in particular sporadic inclusion body myositis, and diagnosis of these diseases based on KDM5A expression levels in muscle tissue. The invention further concerns pharmaceutical compositions comprising KDM5A inhibitors for use in prevention or treatment of idiopathic inflammatory myopathies such as polymyositis, dermatomyositis, necrotizing autoimmune myopathy, and in particular sporadic inclusion body myositis.

Abstract: The invention pertains to an ophthalmological device (100, 200) for the treatment of Limbal Stem Cell Deficiency, the device (100, 200) comprising: a stem cell carrier substrate; and a culture of limbal epithelial stem cells cultivated on said stem cell carrier substrate; wherein said stem cell carrier substrate comprises a hydrogel containing collagen or collagen-mimicking peptides; and wherein a ring-shaped area on a surface of said stem cell carrier substrate is provided with a pattern of niches (110, 210). The invention also pertains to a method for producing the ophthalmological device.

Abstract: Methods use a catalytic composition built up from a ceramic material including a catalytic material and a first inorganic binder and a second inorganic binder and a catalytic structure made thereof. Preferably, the structure is made by a colloidal ceramic shaping technique. The structure is used for catalytic or ion exchange applications. The catalytic structures have excellent mechanical, physicochemical and catalytic properties.

Abstract: The present invention concerns a method for obtaining an implantable plate for healing a fractured joint of a patient, comprising the steps of: 1) providing a 3D representation of a bone structure in a zone around a joint fracture, the zone comprising essentially all fragments of broken or ruptured bones and at least the ends of unbroken bones which form part of the fractured joint; 2) identifying different bone fragments within said 3D representation; 3) simulating a reduction of said bone fragments into a full joint; 4) calculating optimal parameter values for an implantable plate; 5) obtaining the implantable plate taking into account the calculated parameter values, whereby in step 3, the reduction is simulated by automatedly fitting positions and orientations of said bone fragments to a 3D representation of a healthy joint of said patient.

Abstract: The present invention relates to a particulate material separation assembly. It comprises a filtration membrane and an antifouling device. The antifouling device comprises one or more magnets and a plurality of magnetisable particles. The one or more magnets cause the plurality of magnetisable particles to self-assemble into dynamic bristles, thereby forming a brush. The particulate material separation assembly is particularly useful in the context of micro algae harvesting.

Abstract: The present invention relates to the field of combination immunotherapy, more in particular to a combination comprising IL-15 and a CD40 agonist for use in the treatment of cancer, such as and not limited to, pancreatic cancer (e.g. pancreatic ductal adenocarcinoma and pancreatic neuro-endocrine tumours).

Abstract: A method for determining a minimum inhibitory concentration (MIC) to an antimicrobial drug for a bacteria culture in a container, the method comprising calculating for each well a third derivative of said detected intensity; comparing said third derivative of the detected intensity to one or more threshold values; determining a MIC value based on said comparison of said third derivative to said one or more threshold values.

Abstract: A process for the production of a catalyst comprising the steps of: dissolving the requisite quantities of copper nitrate and nickel nitrate in de-ionised water to provide a sub-0.30 molar aqueous solution of copper nitrate and nickel nitrate together in the ratio required; providing an ammoniacal solution by adding concentrated aqueous solution of ammonia in a quantity equal to between six and ten times the quantity required to realise both a 1:6 molar ratio for Cu2+ to ammonia and a 1:6 molar ratio for Ni2+ to ammonia; loading gamma alumina with 1 to 30% w/w of copper and nickel in a weight ratio of nickel to copper of 1:5 to 2:1 by suspending the requisite quantity of gamma alumina in said ammoniacal solution to achieve the required loading of copper and nickel; stirring the resulting gamma alumina suspension for at least 4 h at room temperature; then the volatile components evaporate under ambient conditions leaving dry loaded gamma alumina, which is calcined at a temperature of at least 260° C.

Abstract: A method is disclosed for providing network access by a network stack in a communication device comprising a plurality of physical communication interfaces, each comprising a data link layer for the exchange of data frames with remote communication devices and a data link layer interface for exchanging data of data frames between the data link layer and higher layers in the network stack; and wherein the method comprises i) providing an abstraction data link layer comprising a single abstracted data link layer interface such that the plurality of physical communication interfaces appear as a single data link layer interface to the higher layers; and ii) obtaining network packets from the higher layers and distributing the network packets over the plurality of physical communication interfaces according to a neutral packet distribution scheme.

Abstract: The present invention relates to the field of mucin isoforms, more in particular for use in the diagnosis, monitoring, prevention and/or treatment of a disease characterized by barrier dysfunction, such as but not limited to a gastrointestinal disorder (e.g. Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), cancer, gastro-intestinal infections, obesitas, non-alcoholic fatty liver disease (NAFLD)), neurodegenerative disorders, respiratory infections, . . . In a specific embodiment, said mucin isoform is selected from the list comprising: MUC1 isoforms and MUC13 isoforms.

Abstract: A wireless communication device comprises a control unit, an antenna interface, an active wireless transceiver operable together with the control unit and antenna interface, a passive wireless transceiver operable together with the antenna interface and operable by harvesting power from received radio messages. The device is further configured to deactivate the one or more active wireless transceivers and control unit to an inactive state and, subsequently, by the passive wireless transceiver, activate the control unit and an active wireless transceiver to an active state when the passive wireless transceiver receives a message from the antenna interface.

Abstract: Method (100) for determining an immune responsiveness to a query epitope (126) comprising: receiving sequence data (122) comprising TCR sequences of at least a part of a TCR repertoire of a subject; selecting a predictive model (160) generated or trained using a dataset comprising TCR sequences known to bind specifically to a model epitope, said predictive model selected according to a sequence match between the model epitope and query epitope; querying (130) the selected predictive model (160) with the sequence data (122); determining (140) from outputs of the selected predictive model (160) a Responsiveness Score indicative of the immune responsiveness. The immune responsiveness can be used to predict and optimal vaccine composition and/or evaluate efficacy of a vaccine in a subject or population.

Abstract: The present invention provides a method for the determination of the monoisotopic mass of a macromolecule from a mass Mmono spectrometry spectrum of said macromolecule based on the experimentally determined most abundant mass, with accuracy in the low parts-per-million (ppm) range. The method uses a simple, double-linear model for predicting the monoisotopic mass based on the experimentally determined most abundant mass, comprising the steps of (a) deriving the most abundant mass MMostAb from the spectrum; and (b) calculating the monoisotopic mass MMono from the most abundant mass MMostAb, using MMono=a+?MMOSTAB+?; wherein ? is a scalar slope obtainable by fitting the slope of monoisotopic mass versus most abundant mass for a plurality of macromolecules from a macromolecule database; and ? is a scalar residue of the form ?=?int+sfrac, ?int being an integer, and ?frac being a sawtooth function of MMostAb.

Abstract: The present invention relates to 3-(benzylamino)-4-(cyclohexylamino)-N-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 (Fer-1) analogues as cell death inhibitors by inhibition of ferroptosis and/or oxytosis for the treatment of stroke, myocardial infarction, diabetes, sepsis, the prevention of transplant rejection, neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, dementia with Lewy bodies and Friedreich's ataxia. The present invention further relates to pharmaceutical compositions of these compounds and discloses methods for making the compounds and the corresponding intermediate.

Abstract: The present invention relates to novel isolated bacterial strains of the Dolosigranulum pigrum species and variants thereof having at least 99% sequence identity in its 16S rRNA gene to said novel strains. The present invention further relates to the use of these bacterial strains, and compositions comprising said strains for use as a probiotic, such as for improving or restoring the flora/microbiota of the respiratory tract and skin. The present invention further relates to the use of these bacterial strains as an antibacterial agent; for use in human or veterinary medicine; for use in the treatment of human or veterinary diseases; or for use in personal hygiene industry, food industry, cleaning industry, pharma industry, or biocontrol applications.

Abstract: The invention pertains to a method for determining transmission parameters in a wireless local area network operating under a restricted access window scheme, said wireless local area network comprising an access point and a plurality of stations, the method comprising at said access point: estimating (230) respective transmission intervals and next transmission times of said plurality of stations; and assigning (260) a subset of said plurality of stations to a restricted access window group on the basis of said estimated next transmission times. The invention also pertains to a computer program product comprising code means configured to cause a processor to carry out the method and an access point configured to carry out the method.